A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer
Status:
RECRUITING
Trial end date:
2028-06-02
Target enrollment:
Participant gender:
Summary
This is a first-in-human, open-label, dose-escalation, dose-optimization trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of MEN2501 monotherapy in adult participants with platinum-resistant ovarian cancer.